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TFIIH is a high molecular weight complex with a re-
markable dual function in nucleotide excision repair
and initiation of RNA polymerase II transcription. Mu-
tations in the largest subunits, the XPB and XPD heli-
cases, are associated with three inherited disorders: xe-
roderma pigmentosum, Cockayne’s syndrome, and
trichothiodystrophy. To facilitate the purification and
biochemical characterization of this intricate complex,
we generated a cell line stably expressing tagged XPB,
allowing the immunopurification of the XPB protein
and associated factors. Addition of two tags, a N-termi-
nal hexameric histidine stretch and a C-terminal hemag-
glutinin epitope, to this highly conserved protein did
not interfere with its functioning in repair and tran-
scription. The hemagglutinin epitope allowed efficient
TFIIH immunopurification to homogeneity from a frac-
tionated whole cell extract in essentially one step. We
conclude that the predominant active form of TFIIH is
composed of nine subunits and that there is one mole-
cule of XPB per TFIIH complex. The affinity-purified
complex exhibits all expected TFIIH activities: DNA-de-
pendent ATPase, helicase, C-terminal domain kinase,
and participation in in vitro and in vivo nucleotide ex-
cision repair and in vitro transcription. The affinity pu-
rification procedure described here is fast and simple,
does not require extensive chromatographic proce-
dures, and yields highly purified, active TFIIH.
Nucleotide excision repair (NER)1 is a versatile DNA repair
mechanism that removes a wide variety of lesions, such as
UV-induced lesions and numerous chemical adducts (1, 2). The
principal steps in the reaction mechanism of NER are recogni-
tion and demarcation of the lesion, probably involving chroma-
tin remodelling and local helix opening, incision of the DNA on
both sides of the lesion at some distance, removal of the dam-
aged oligonucleotide, and, finally, repair DNA synthesis and
ligation. In eukaryotes, this reaction requires about 30 poly-
peptides and has been reconstituted with purified components,
including XPA, XPC/HHR23B, replication protein A, the struc-
ture-specific nucleases ERCC1/XPF and XPG, and the multi-
subunit basal transcription factor TFIIH (3–5). At least two
subpathways can be discerned in the NER system. One of
these, transcription-coupled repair, preferentially removes
DNA damage from the transcribed strand of active genes,
whereas lesions in the rest of the genome are repaired more
slowly and less efficiently by the global genome repair path-
way. TFIIH appears to be a core component of both excision
subpathways.
Mutations in the two largest subunits of TFIIH, the XPB and
XPD helicases, are associated with the rare genetically heter-
ogeneous disorders xeroderma pigmentosum (XP), Cockayne’s
syndrome (CS), and trichothiodystrophy (TTD) (6, 7). Many
complementation groups and considerable overlap have been
established for these syndromes: seven complementation
groups in XP (XP-A–XP-G), three of which include patients
with combined XP and CS phenotypes (XP-B, XP-D and XP-G),
two in the classical form of CS (CS-A and CS-B), and three in
TTD (XP-B, XP-D, and TTD-A). The discovery of the dual
function of XPB and XPD in both NER and transcription pro-
vides a rationale for the complex clinical features that are
specifically associated with inherited defects in TFIIH sub-
units, such as seen in the combined XP/CS and the photosen-
sitive form of TTD, that were difficult to explain solely on the
basis of a NER defect. Thus, it was proposed that typical XP
characteristics, such as UV-induced cutaneous abnormalities
and predisposition to skin cancer, are due to inactivation of the
NER function of TFIIH, whereas features typical for CS and/or
TTD, such as neurodysmyelination, brittle hair, and growth
defects, are due to a deficiency in the transcription function of
TFIIH, possibly affecting only a subset of genes (8).
In addition to XPB and XPD, which exhibit DNA-dependent
ATPase activities and are 39-59 and 59-39 DNA helicases, re-
spectively (9, 10), seven more TFIIH subunits have been iden-
tified to date. CDK7 was identified as the catalytic subunit of
the kinase activity of TFIIH that is able to phosphorylate the
C-terminal domain (CTD) of the largest subunit of RNA polym-
erase II (11). Interestingly, CDK7 also constitutes a separate
trimeric kinase complex that is possibly involved in cell cycle
regulation together with the cyclin H and MAT1 subunits of
TFIIH (12, 13). Furthermore, p44, the human homologue of
yeast SSL1, and p34 contain zinc finger domains and possess
putative DNA binding capacity (14). So far, no activity has been
detected for the p62 and p52 subunits (15, 16). Whether these
nine proteins constitute the TFIIH complex and whether the
composition of TFIIH differs during NER and transcription
initiation are yet unresolved issues.
The presence of two DNA helicases has implicated TFIIH in
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a helix-opening step during both transcription initiation and
NER. It has been shown that such open-complex formation at
the transcription start site depends on TFIIH and that the
requirement for TFIIH is dependent on promoter topology and
can be alleviated by premelted regions at the transcription
start site (17–19). During NER, TFIIH is thought to convert a
recognized damaged site into a substrate for the XPG and
XPF/ERCC1 structure-specific nucleases by locally opening
DNA around a lesion. The formation of an opened DNA confor-
mation around a recognized lesion has been demonstrated;
however, the direct involvement of TFIIH in this step has not
been shown (20). Answers to these questions are hampered by
the difficulty in obtaining large quantities of highly purified
TFIIH. Therefore, we developed a procedure that facilitates the
isolation of TFIIH using a human cell line expressing func-
tional XPB provided with two tags. The affinity purification
procedure described here is fast and simple, does not require
extensive chromatographic procedures, and yields highly puri-
fied, active TFIIH.
EXPERIMENTAL PROCEDURES
General—Purification of nucleic acids, restriction enzyme digestion,
gel electrophoresis of nucleic acids and proteins, immunoblotting, de-
tection of proteins and nucleic acids were performed according to stand-
ard procedures (21).
Oligonucleotides and Plasmid DNA Construction—The coding se-
quence for the C-terminal HA epitope tag was added via PCR using
oligonucleotide primer pairs p90 59-CCCGGATCCTCAGCTAGCGTA-
ATCTGGAACATCGTATGGGTATTTCCTAAAGCGCTTGAAG-39 (39
primer; underlined sequence encodes the HA epitope, and double un-
derlined sequence indicates a BamHI restriction site) and p33 59-
GGATCCACCATGGGCAAAAGAGACCG-39 (59 primer). Likewise, the
hexahistidine tag was added using oligonucleotides p123 59-CGCGCG-
GAATTCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGG-
CCTGGTGCCGCGCGGCAGCCATATGGGCAAAAGAGACCG-39 (59
primer; underlined sequence encodes a hexahistidine stretch and
thrombin cleavage site, and double underlined sequence indicates an
EcoRI site) and p41 59-CGGGAAGTGGAGGGCCCACC-39 (39 primer).
PCR fragments were cloned, sequenced, and confirmed to be free of
PCR-introduced sequence errors. Full-length XPB and double-tagged
XPB cDNA (dtXPB cDNA) were subcloned as EcoRI-BamHI fragments
in a modified pSG5 eukaryotic expression vector yielding plasmids
pSHE3 and pSHE3HA, respectively. From pSHE3HA, the dtXPB cDNA
was subcloned as a EcoRI-XhoI fragment in the eukaryotic expression
vector pcDNA3 (Invitrogen) yielding plasmid pM300.
DNA Transfection and UV Survival Assay—Cells were cultured in a
1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F-10
medium supplemented with 10% fetal calf serum and antibiotics. HeLa
TK2 cells were transfected with vector pM300 by electroporation, and
after selection with 1.0 mg/ml G418, individual clones were selected for
expression of dtXPB by immunoblot analysis using anti-XPB
antibodies.
Cell lines XP-wt and XP-t3 were generated by transfection of
XPCS2BASV (XP-B) SV40-immortalized fibroblasts with XPB and
dtXPB cDNA, respectively. Expression vector pSHE3 or pSHE3HA and
a neomycin-selectable marker, were cotransfected using Lipofectin re-
agent essentially as described by the manufacturer (Life Technologies,
Inc.). Stably expressing mass populations were obtained by selection
with 300 mg/ml G418 and repeated UV irradiation at 1 day intervals
(three doses of 4 J/m2).
UV survival was assayed by [methyl-3H]thymidine incorporation 3
days after irradiation as described (22). Proliferating cells were pulse-
labeled with [methyl-3H]thymidine (3 h) and then chased (1 h). Cell
lysates were transferred to scintillation-counting vials, and survival
was calculated as the average ratio of incorporated radiolabel in treated
triplicates to that in four untreated control dishes.
Immunopurification of dtXPB Protein and Associated Factors—
XP-t3 cells were cultured in suspension in RPMI 1640 medium supple-
mented with 10% fetal calf serum and antibiotics. Whole cell extracts
(WCEs) (total, 530 mg) were prepared from frozen cell pellets (total, 50
ml packed cell volume) as described (23). Subsequently, WCEs were
fractionated on heparin-Ultrogel (IBF, France) equilibrated in Buffer A
(10 mM Tris-HCl, pH 7.8, 17% glycerol (v/v), 0.5 mM dithiothreitol, 5 mM
MgCl2) containing 0.1 M KCl and eluted with Buffer A containing 0.22,
0.4, and 1.0 M KCl as described (24). All of the dtXPB protein was
present in the 0.4 M KCl fraction (designated Hep0.4; 175 mg of protein)
as judged by immunoblot analysis similar to TFIIH. Typically, 10–12
ml (7.5–9.0 mg of protein) of the Hep0.4 fraction was successively
incubated with 400 mg of purified 12CA5 anti-HA monoclonal antibody
bound to 400 ml of protein G-Sepharose (Pharmacia Biotech Inc.) over-
night at 4 °C. The resin was washed three times with 10 volumes of
ice-cold buffer T (25 mM Tris-HCl, pH 7.9, 17% glycerol (v/v), 0.5 mM
EDTA, 0.2 mM dithiothreitol, 5 mM MgCl2) containing 0.4 M KCl and
0.1% Nonidet P-40 and twice with buffer T/0.1 M KCl containing 0.01%
Nonidet P-40. Bound material was eluted for 1 h at 30 °C in 400 ml of
buffer T/0.1 M KCl containing 0.01% Nonidet P-40, 0.2 mg/ml insulin,
2.0 mg/ml synthetic peptide corresponding to the HA epitope (sequence
YPYDVPDYA), and 1.0 mg/ml aprotinin. This step was repeated once or
twice. Routinely, nearly all dtXPB and associated factors were present
in the first eluate as detected by immunoblotting. Purified proteins
were stored at 280 °C.
The same procedure was used for immunoprecipitation of dtXPB
directly from a WCE (15 mg) to analyze protein-protein interactions.
However, in this case, bound material was washed five times with
buffer containing 0.1 M KCl, 0.1% Nonidet P-40 and analyzed by im-
munoblotting after overnight elution at 4 °C with buffer containing 1.0
mg/ml peptide and 0.1 mg/ml bovine serum albumin (Sigma).
Microneedle Injection—Prior to microinjection, human primary fibro-
blasts were fused by inactivated Sendai virus as described earlier (8).
Protein fractions were microinjected into the cytoplasm of XP polykary-
ons, and NER activity was measured by pulse labeling with [methyl-
3H]thymidine and in situ autoradiography as described (8). Repair
activity was quantified by counting autoradiographic grains above at
least 50 non-S phase nuclei. Primary cell lines used were XPCS1BA
(XP-B), XP6BE (XP-D), XP126LO (XP-F), XP3BR (XP-G), TTD1BR
(TTD-A), and C5RO (wild type).
In Vitro NER Assay—WCEs were prepared from repair-proficient
HeLa and XP-t3 cells and repair-deficient SV40-immortalized
XPCS2BASV (XP-B) cells (23). NER reactions (50 ml) contained 250 ng
of plasmid DNA randomly damaged with N-acetoxy-2-acetylaminoflu-
orene and as an internal control an equal amount of undamaged control
plasmid of a different size, the indicated amount of extract, and purified
proteins; the reactions were incubated for 3 h at 30 °C. DNA was
purified, linearized with BamHI, and analyzed on a 0.8% agarose gel
(25, 26). Antibody depletion of extracts was performed as follows: for
each reaction, 100 mg of WCE was incubated with 0.5 ml of anti-p62
ascites and 5 ml of protein G-agarose overnight at 4 °C. For the exper-
iment shown in Fig. 6A, plasmid DNA was randomly damaged with
cis-diaminedichloro-platinum(II) (16).
In Vitro Transcription Assay—Purified TFIIH was incubated with
recombinant human TBP, TFIIB, and TFIIE and purified TFIIA,
TFIIF, and RNA polymerase II as described earlier (24). After 15 min of
preincubation at 25 °C with 70 ng of linearized template DNA contain-
ing the adenovirus 2 major late promoter, nucleotides were added, and
transcription was allowed to proceed in a final reaction volume of 25 ml
for 45 min at 25 °C. The 309-nucleotide runoff transcripts were ana-
lyzed by electrophoresis through a 5% acrylamide/50% urea gel.
Enzymatic Assays—ATPase reactions contained 20 mM Tris-HCl, pH
7.9, 4 mM MgCl2, 1 mM dithiothreitol, 50 mg/ml bovine serum albumin,
150 ng of DNA and were performed essentially as described before (27).
After 30 min of incubation at 37 °C, 25-ml reactions were stopped by
adding 2 ml of 0.5 M EDTA and 25 ml of TE (10 mM Tris-HCl, pH 8.0, 0.1
mM EDTA). Of each reaction, 1 ml was analyzed by thin-layer chroma-
tography using polyethylenimine-cellulose plates (Merck) run in 0.75 M
KH2PO4. CTD kinase assays (20 ml) containing 20 mM Hepes-KOH, pH
7.9, 20 mM Tris-HCl, pH 7.9, 7 mM MgCl2, 0.5 mg/ml bovine serum
albumin, and 30 mM KCl were performed with 10 mg of a synthetic
tetrapeptide of YSPTSPS as a substrate as detailed before (27). DNA
helicase probes were prepared as described (27), and reactions (25 ml)
contained 20 mM Tris-HCl, pH 7.9, 4 mM MgCl2, 1 mM dithiothreitol, 50
mg/ml bovine serum albumin, 2 mM ATP, and 1 ng of DNA substrate and
were incubated at 37 °C for 45 min. Displacement of the 24-mer oligo-
nucleotide from M13mp18 single-stranded DNA was analyzed by 10%
nondenaturing polyacrylamide gel electrophoresis and autoradiography
(27).
Antibodies—The monoclonal antibodies recognizing TFIIH subunits
were all described before (10, 12, 14–16). Monoclonal antibodies recog-
nizing the HA epitope (28) were purified from 12CA5 hybridoma tissue
culture supernatant by affinity chromatography on protein G-agarose
according to established protocols (29).
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RESULTS
Generation of a Cell Line Expressing Tagged XPB—To ana-
lyze interactions of the XPB protein with other proteins, in-
cluding TFIIH under physiological conditions, and to facilitate
the purification of active TFIIH, we decided to generate a
human cell line stably expressing a tagged version of XPB
(dtXPB) cDNA. To permit isolation of full-length XPB protein
and allow purification of XPB on the basis of different revers-
ible affinity purification steps, we chose to add two different
types of tags, one on each end of the protein. Thus, coding
sequences for a N-terminal hexahistidine stretch followed by a
thrombin cleavage site and a C-terminal HA epitope tag (28,
30) were added to XPB cDNA fragments, and a full-length
double-tagged XPB cDNA was constructed (Fig. 1A) and sub-
cloned in eukaryotic expression vectors. To obtain cell lines
stably expressing dtXPB, the cDNA vectors were transfected to
two human cell lines. First, dtXPB cDNA and a neomycin-
selectable marker were transfected into HeLa cells. After se-
lection with G418, individual HeLa clones were obtained and
analyzed by immunoblotting for the level of the dtXPB protein
using anti-XPB antibodies. As shown in Fig. 1B, lanes 1–5, the
double-tagged XPB can be conveniently discerned from the
endogenous wild type XPB protein because of its increased size
(the predicted molecular mass increases from 89,279 Da to
92,690 Da). In the 48 clones analyzed, various levels of dtXPB
protein were detected in WCEs, with many clones expressing
no or hardly detectable dtXPB, despite the fact that the dtXPB
cDNA was under the control of the strong cytomegalovirus
promoter, and multiple copies are expected to be integrated in
the genome. Interestingly, in neither case did we observe a
large overexpression, and clones expressing the highest level of
dtXPB clearly showed decreased levels of the wild type endog-
enous protein as compared with the p62 core subunit of TFIIH
(e.g. Fig. 1B, compare clone 1-19 with clones 1-6, 1-2, and 1-7).
These findings suggest that the cellular content of XPB is kept
within narrow concentration ranges by degrading excess pro-
tein and that there is competition between the endogenous wild
type and exogenous tagged protein. Secondly, XP-B UV-sensi-
tive cells were transfected, and after selection with G418 and
repeated UV irradiation, a stably expressing mass population
was established, designated XP-t3. As with the HeLa transfec-
tants, immunoblot analysis of XP-t3 cell extracts indicated that
dtXPB protein levels were comparable with the endogenous
(mutant) XPB levels (Fig. 1B, lanes 6–8). Because the rela-
tively high dtXPB protein levels in HeLa clone 1-19 varied
during culturing and appeared to be more stable in the trans-
fected XP-B cells, the XP-t3 cell line was further characterized
and used for all experiments described here.
To characterize the functionality of the dtXPB protein in
vivo, an UV survival experiment was carried out. Fig. 1C shows
that dtXPB is able to reverse the UV sensitivity of XP-B cells to
the same extent as wild type XPB cDNA, although both not to
the same level as the wild type MRC5 transformed cell line
used as a repair-proficient control. The NER activity was fur-
ther analyzed using an in vitro assay. WCEs were prepared and
incubated in the presence of both damaged and undamaged
plasmid DNA and labeled nucleotides. The resulting incorpo-
ration of labeled nucleotides in the damaged plasmid DNA is
due to repair DNA synthesis and a measure for NER activity.
Fig. 1D shows that extracts prepared from XP-t3 cells were
able to repair N-acetoxy-2-acetylaminofluorene-damaged DNA
in vitro, whereas extracts prepared from XP-B cells display a
strongly reduced repair activity. The above findings indicate
that the dtXPB protein is functional in NER, implying that it
most likely is incorporated in the TFIIH complex. Finally, the
fact that these cells grow normally strongly suggests that the
dtXPB protein is not interfering with the basal transcription
initiation function of the complex.
Analysis of TFIIH Factors Associated with dtXPB Pro-
FIG. 1. Analysis of the XP-t3 cell line expressing dtXPB. A,
schematic representation of the dtXPB protein. Indicated are the hexa-
histidine stretch ((HIS)6), the thrombin cleavage site (T), and the HA
epitope tag (HA). B, immunoblot analysis of cloned HeLa transfectants
and the XP-t3 cell line containing varying levels of dtXPB protein. Due
to the increased size of the double-tagged XPB, the protein migrates at
a higher molecular mass. Lanes 1–5, HeLa clones containing varying
levels of dtXPB protein; lane 6, wild type immortalized fibroblast
(VH10); lane 7, XP-B immortalized fibroblast (XPCS2BASV); lane 8,
XP-t3 transfected XP-B (XPCS2BASV) fibroblast. Indicated are the
endogenous and tagged XPB proteins and the p62 subunit, used as
internal reference for the amount of TFIIH in each lane. The p62
subunit appears in lanes 6–8 as a doublet due to posttranslational
modifications (T. Seroz, J. Auriol, and J.-M. Egly, unpublished results).
C, dtXPB is functional in DNA repair. UV survival of XPCS2BASV
(XP-B) fibroblasts and transfectants expressing tagged and wild type
XPB cDNA (XP-t3 and XP-wt, respectively). As a wild type control,
MRC5 immortalized fibroblasts were used. D, in vitro NER activity
measured in WCEs from HeLa (lanes 1–3), XP-t3 (lanes 4–6), and XP-B
(lanes 7–9) cells using N-acetoxy-2-acetylaminofluorene-damaged plas-
mid DNA as substrate. Of each WCE, 50, 100, and 150 mg was used,
respectively. Upper panel, ethidium bromide-stained gel of the linear-
ized damaged and undamaged plasmids; lower panel, corresponding
autoradiogram.
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tein—To identify proteins interacting with XPB, an immuno-
precipitation experiment was carried out under physiological
salt conditions (0.1 M KCl) using a repair- and transcription-
competent XP-t3 WCE. As shown in Fig. 2, the dtXPB protein
could be specifically and quantitatively immunoprecipitated
using anti-HA monoclonal antibodies, and in addition to
dtXPB, we could detect several TFIIH subunits in the bound
fraction (XPD, p62, CDK7, and cyclin H). This confirms that
dtXPB was incorporated in TFIIH. Furthermore, the fact that
the relative intensities of XPB versus p62 are not significantly
altered in the load, unbound, and the bound fractions indicates
that the established XP-t3 cells harbor dtXPB in the majority of
the TFIIH complexes. Interestingly, although all dtXPB pro-
tein was depleted from the WCE, none of the endogenous
(mutant) XPB was detected in the bound fraction. This demon-
strates that only one XPB subunit is present per complex: if the
complex contained more than one XPB molecule, complexes
with both the endogenous (mutant) subunit and the tagged
protein would be expected to be present in the bound material.
Immunopurification of XPB and Associated Factors—Be-
cause a number of TFIIH subunits specifically co-immunopre-
cipitated with dtXPB protein using anti-HA antibodies, we set
out to purify TFIIH on this basis and analyze the composition
of the TFIIH complex (Fig. 3A). First, WCEs from XP-t3 cells
were fractionated on heparin-Ultrogel as described (24). All
dtXPB protein, as well as XPB and other known TFIIH sub-
units, were present in the 0.4 M KCl fraction, designated
Hep0.4. Portions of this fraction were directly incubated with-
out further fractionation with anti-HA resin to purify dtXPB
and associated proteins. After incubation, the anti-HA resin
was extensively washed, and bound material was eluted by
competition with excess HA peptide. Subsequently, the compo-
sition of the eluate was analyzed by SDS-polyacrylamide gel
electrophoresis and staining with silver nitrate. In addition to
dtXPB, we identified only eight polypeptides ranging in molec-
ular mass from 80 to 34 kDa that specifically and consistently
immunoprecipitated with dtXPB and are thus XPB-associated
factors (Fig. 3B). These associated proteins were all identified
as known TFIIH subunits by two criteria: (i) reactivity with
monoclonal antibodies specifically recognizing TFIIH subunits;
and (ii) exact co-migration with known TFIIH subunits in SDS-
polyacrylamide gel electrophoresis (data not shown). Finally, the
staining intensity of the dtXPB subunit, compared with the other
subunits, suggests that the dtXPB protein was predominantly
present in stoichiometric amounts and not in a free form.
Presence of Additional NER and Transcription Factors in the
Affinity-purified TFIIH Fraction—A number of NER and basal
transcription factors (TFIIE, CSA, CSB, and XPG, among oth-
ers) have been described to interact with the TFIIH complex,
either as part of a RNA polymerase II holoenzyme (31, 32) or
using isolated proteins (33, 34). Therefore, it was unexpected to
find only nine polypeptides stained by silver nitrate in the
immunopurified fraction. The silver-stained protein profile of
affinity-purified TFIIH (Fig. 3B) does not exclude the possibil-
ity that substoichiometric amounts of other NER or transcrip-
tion factors are present. Furthermore, the heparin fraction-
ation might have disrupted salt-sensitive interactions.
Therefore, the TFIIH-containing fraction that was immunopre-
cipitated directly from a WCE using low salt conditions was
tested by immunoblot analysis for the presence of additional
NER and transcription factors (Fig. 4). However, we were not
able to detect the presence of any of the NER factors ERCC1,
XPC, HHR23B, XPG, and CSB, RNA polymerase II, or any
significant levels of the basal transcription factors tested. The
absence of a stable interaction with CSB was confirmed by the
reverse experiment, in which tagged CSB was immunoprecipi-
tated and analyzed for the presence of TFIIH subunits (46). As
a positive control, we detected the presence of the human
homologue of yeast SUG1, a protein that we recently identified
to interact with the XPB subunit of TFIIH (35). Notably, hu-
man SUG1 was below immunodetection level in the immuno-
purified fraction shown in Fig. 3B, indicating that this inter-
action was salt-sensitive under the conditions used. Similar
results were obtained using fractionation of the WCE on a
Ni-NTA column that has a high affinity for the hexahistidine
stretch or by using a nuclear extract preparation (data not
shown). The above results indicate that the interactions of
TFIIH with the various NER and transcription factors are, at
least under the various conditions we used, not stable.
Functional Characterization of Affinity-purified TFIIH—To
determine whether the nine polypeptides identified in the sil-
ver-stained gel represent the active form of TFIIH, we tested
whether the enzymatic DNA-dependent ATPase, DNA heli-
case, and CTD kinase activities that are associated with TFIIH
were present in our purified preparations (27, 36). As shown in
FIG. 2. Immunoblot analysis of TFIIH factors associated with
dtXPB in XP-t3 WCE using HA-antibody immunoprecipitation;
dtXPB is incorporated in the TFIIH complex. Indicated are the
load (WCE), unbound (supernatant), and bound material (eluted with
excess HA peptide). Because the amount of TFIIH was smaller in the
lanes containing the load and unbound material, XPD appears as a very
weak band in these two lanes as compared with the lane containing the
bound fraction. The positions of the molecular weight markers used and
the proteins detected by immunoblotting are indicated.
FIG. 3. Immunopurification of
dtXPB protein and associated fac-
tors. A, schematic representation of the
purification strategy. B, analysis of two
independent anti-HA eluate preparations
(10 ml) by 11% SDS-polyacrylamide gel
electrophoresis stained with silver ni-
trate. The bands marked with asterisks
(*) are also present in the empty lane and
represent staining artifacts.
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Fig. 5A, the ATPase activity detected was dependent on the
presence of DNA and strongly stimulated by either circular
M13 single-stranded or double-stranded supercoiled plasmid
DNA. In addition, the DNA helicase and CTD kinase activities
were readily detected (Fig. 5, B and C). In contrast, we were not
able to detect any DNA nicking or exonuclease activity in the
anti-HA fraction (data not shown).
Next, we tested the transcriptional activity of the anti-HA
eluate (Fig. 5D). Addition of the purified complex was abso-
lutely required in a fully defined reconstituted RNA polymer-
ase II transcriptional reaction using the adenovirus 2 major
late promoter. The anti-HA eluate contained only detectable
TFIIH activity because omitting either TBP, TFIIB, TFIIE, or
TFIIF abolished transcription completely, whereas omitting
TFIIA resulted in a strongly decreased signal, in agreement
with a stimulatory role for TFIIA in defined transcription re-
actions (Fig. 5D). These findings indicate the absence of detect-
able contaminating transcriptional activities in the TFIIH
preparation. A quantitation of the enzymatic and transcrip-
tional assays is presented in Fig. 5, E and F.
Finally, we characterized the activity of the affinity-purified
TFIIH in in vitro NER assays. As shown in Fig. 6A, the affinity-
purified complex was able to complement the NER defect in
XP-B extracts. Quantitation of the incorporated labeled nucle-
otides in the damaged DNA allowed us to estimate the yield of
active TFIIH, which was calculated to be ;12% (Table I),
indicating that the anti-HA elution is rather efficient. Theoret-
ically, the in vitro complementation could also be due to ex-
change of XPB with other TFIIH subunits. Therefore, we per-
formed an antibody depletion experiment. Using anti-p62
antibodies, a HeLa WCE was depleted of TFIIH, which resulted
in a co-depletion of NER activity (Fig. 6B, compare lane 1 with
lanes 6 and 7). As shown (Fig. 6B, lanes 2–5), the anti-HA
eluate restored NER activity in the depleted HeLa WCE up to
the level of the nondepleted extract, indicating that TFIIH
complex formation involving XPB and p62 is essential for NER
activity (25).
To analyze in more detail the NER activities of the purified
TFIIH in vivo, a microneedle injection experiment was carried
out. As anticipated, a strong stimulation of unscheduled DNA
synthesis was readily observed directly after microinjection in
XP-B and XP-D polykaryons, which was specific because it was
not seen in XP-F and XP-G cells (Fig. 7, A and C). Interestingly,
correction was also observed in TTD-A cells (Fig. 7, B and C)
that contain a mutation in an as yet unidentified NER factor
(37), in agreement with our earlier findings using highly puri-
fied TFIIH from HeLa cells by classical purification (8). These
experiments indicate that TTDA either is an intrinsic compo-
nent of TFIIH or is required for a modification of TFIIH, ena-
bling it to function in repair (see “Discussion”).
In conclusion, these experiments show that the immunopu-
rification of dtXPB and associated proteins result in the rapid
and efficient purification of TFIIH, which is active in NER and
transcription.
FIG. 4. Association of TFIIH with NER and transcription fac-
tors. None of the tested NER and/or basal transcription factors showed
detectable association with TFIIH immunoprecipitated using HA-anti-
bodies. As a positive control, human SUG1 was identified in the bound
fraction. Antibodies used to identify multisubunit complexes recognized
the p62 subunit of TFIIH, the RPB1 subunit of RNA polymerase II, the
34-kDa b-subunit of TFIIE, and the RAP74 subunit of TFIIF. Indicated
are the load (WCE) and the bound fraction (eluted with excess HA
peptide).
FIG. 5. Analysis of TFIIH enzymatic
and transcriptional activities in an-
ti-HA eluates. A, ATPase activity is
strongly stimulated by single-stranded
DNA (ss-DNA, M13mp18, 150 ng) or dou-
ble-stranded DNA (ds-DNA, plasmid
DNA, 150 ng). Increasing amounts of an-
ti-HA affinity-purified TFIIH were used to
measure ATPase activity (1, 2, and 4 ml). B,
DNA helicase activity detected by displace-
ment of a 24-mer oligonucleotide from
M13mp18 single-stranded DNA. Indicated
are increasing amounts of anti-HA eluate
(1, 2, 3, and 4 ml). C, CTD kinase activity by
increasing quantities of anti-HA eluate (1,
2, 3, and 4 ml). D, TFIIH transcriptional
activity is present in anti-HA eluate. Indi-
cated are increasing amounts of anti-HA
eluate (0, 1, 2, 3, and 4 ml) added to a
complete reaction or individual transcrip-
tion factors omitted from the reaction con-
taining anti-HA eluate (4 ml). E, quantita-
tion of the ATPase and DNA helicase
activities. The ATPase activity is repre-
sented by the percentage of ATP hydro-
lyzed in the absence of DNA (l), and in the
presence of single-stranded DNA () and
double-stranded DNA (). The helicase
activity is depicted by the percentage oli-
gonucleotide displaced from the single-
stranded DNA (E). F, quantitation of the
CTD kinase (l) and transcriptional activ-
ities (E). Both the CTD kinase and tran-
scription are represented in arbitrary
units (A.U.).
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DISCUSSION
TFIIH was originally purified as a basal transcription factor
from rat, yeast, and human (24, 38–40) and was first shown by
Schaeffer et al. (9) to be involved in NER; this involvement was
subsequently demonstrated by others as well (25, 33, 41). By
immunopurifying the XPB protein using a cell line expressing
functional tagged XPB, we describe an improved and facilitated
purification for TFIIH free of contaminating NER and tran-
scriptional activities that is an efficient, essentially one-step,
procedure utilizing physiological elution conditions.
Utilizing this protocol, which avoids the high salt and hydro-
phobic chromatography conditions of the classical purification
procedure, we identify TFIIH as a nine-subunit complex. In
addition, we show that each complex contains only one mole-
cule of the XPB helicase. The intensity of protein staining of the
XPD subunit in the purified complex compared with XPB is
consistent with the idea that the XPD helicase, also, is present
on a molar basis in the complex. The occurrence of two helicase
molecules per TFIIH complex is in agreement with the concept
that the functional forms of a number of helicases are oli-
gomers, generally dimeric or hexameric (42). As reported pre-
viously, CDK7 and cyclin H, together with MAT1, are part of
both TFIIH and a separate trimeric complex in the cell (13).
This is consistent with our findings in the immunoprecipitation
experiment that CDK7 and cyclin H are relatively more abun-
dant in the WCE and unbound fraction as compared with the
XPB-associated fraction (see Fig. 2).
During the past years, all eight XPB-associated factors were
identified and cloned as TFIIH subunits purified from both
HeLa cells and from the budding yeast Saccharomyces cerevi-
siae (16, 43), suggesting that in solution in repair- and tran-
scription-competent WCEs, at least the major form of TFIIH is
composed of nine subunits and is active in NER, as well as
transcription. However, the possibility cannot be excluded that
substoichiometric and/or poorly stained subunits are essential
for, for example, NER functioning, and therefore, definite proof
that both the NER and transcriptional activity of TFIIH re-
sides with the nine identified and cloned subunits awaits re-
FIG. 6. NER activity of affinity-purified TFIIH in vitro. A, in vitro complementation of XP-B NER-deficient WCE (150 mg) by fractions from
the XPB purification (lane 1, XP-B extract alone; lane 2, XP-B extract with 2 ml of Hep0.4 fraction; lanes 3–5, XP-B extract containing 2, 5, and
10 ml, respectively, of anti-HA fraction). Upper panel, ethidium bromide-stained gel; lower panel, autoradiogram. B, depletion of NER activity from
HeLa WCE (100 mg/reaction) with anti-p62 monoclonal antibodies and restoration of NER activity with anti-HA eluate. Lane 1, depleted extract;
lanes 2–5, depleted extracts containing 2, 4, 6, and 8 ml of anti-HA eluate, respectively; lane 6, mock-depleted extract; lane 7, nondepleted extract.
Upper panel, ethidium bromide-stained gel; lower panel, autoradiogram.
FIG. 7. Correction of NER defect by microinjected affinity-
purified TFIIH in XP-B, XP-D, and TTD-A cells in vivo. A and B,
micrographs showing the effect on NER activity of injection of the
anti-HA eluate in XP-B (A) and TTD-A (B) cells. The injected fibroblasts
(polynuclear, obtained by cell fusion prior to injection) are indicated by
arrows. The heavily labeled cell in A is a noninjected S phase cell. C,
quantitation of NER activity of injected XP and TTD-A polykaryons.
The bars represent the average unscheduled DNA synthesis (UDS)
level (obtained by counting grains above 50 nuclei), and S.E. values are
indicated. As a control, unscheduled DNA synthesis of parallel-treated
uninjected wild type fibroblasts (C5RO) were counted and arbitrarily
set at 100%. Open bars, noninjected cells; closed bars, injected cells.
TABLE I
Purification of the TFIIH complex using the dtXPB protein
Fraction Protein Activitya Yield
mg units %
WCE 54.4 —b
Hep0.4 17.5 1731 100
Anti-HA —c 208 12
a One unit of activity was defined as the amount of protein used to
increase the incorporation 2-fold relative to the receiving XP-B extract
(45).
b Activity of the WCE could not be determined.
c Protein concentrations were determined using the BCA protein
assay (Pierce) and could not be reliably determined for the anti-HA
fraction.
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constitution of TFIIH from recombinant proteins.
One of the TFIIH factors that is not yet assigned to a subunit
is TTDA. We are presently investigating whether any of the
known TFIIH genes are mutated in TTD-A cells. However, it is
theoretically also possible that TTDA is not a subunit of the
TFIIH complex itself but is implicated in TFIIH modification as
part of its function. Recently, we have identified human SUG1
as a protein interacting with the XPB subunit of TFIIH (35).
Little is known about posttranslational regulation of TFIIH
function and the role of factors like SUG1 that are thought to
unfold or refold proteins in the context of several processes,
including regulated proteolysis. Like SUG1, TTDA could play a
role in TFIIH modification without being part of the complex.
The inability to generate high levels of dtXPB protein, even
when the cDNA was expressed under control of strong promot-
ers, suggests an autoregulatory mechanism of XPB protein
levels. For example, a similar observation was made in the case
of overexpression of the NER protein ERCC1, which forms a
complex with XPF, and TBP, which is part of the basal tran-
scription factor TFIID (22, 44).
Using NER- and transcription-competent WCEs, physiolog-
ical washing conditions, and nonoverexpressed functional
dtXPB protein, we failed to observe, within our limits of detec-
tion, interactions with any NER and/or transcription factor
tested, although some of them were reported previously by
others (31–34). Several explanations can be put forward for this
apparent discrepancy. Many methods for identification of pro-
tein-protein interactions use overexpressed, in vitro synthe-
sized or purified proteins often involving heterologous expres-
sion systems. When the protein normally resides in a complex
and has multiple interaction domains, it may exhibit promis-
cuous association behavior when studied in isolation because of
the lack of its natural partners, improper folding, or lack of
posttranslational modification. Alternatively or in addition, the
interactions observed were not stable during our extract prep-
arations and/or were transient or induced upon DNA binding.
The procedure described here greatly facilitates the isolation of
active TFIIH. It is simple, fast, and reproducible and does not
require extensive chromatographic procedures. In combination
with specific procedures for extract preparation, it may be ex-
ploited further for the purification of holo-complexes involved in
NER and/or transcription. Furthermore, this procedure may al-
low the isolation of TFIIH with mutated XPB subunits for bio-
chemical analyses to obtain more insight into the requirements
for the XPB helicase-mediated function in NER and transcription
initiation. Because the reconstitution of TFIIH from recombinant
source is lacking at this moment, it would also be of interest to
add (epitope) tags to other TFIIH subunits for functional anal-
ysis of TFIIH with mutations in, for example, the second heli-
case subunit, XPD. These experiments are in progress.
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